An evaluation method for uric acid uptake inhibition using primary human proximal tubule epithelial cells treated with insulin

Abstract The effects of uricosuric agents have been evaluated in vitro with indices of uric acid uptake into human urate transporter 1 (URAT1)-overexpressed oocytes or cells. In the present study, we evaluated a method using primary human renal proximal tubule epithelial cells (RPTECs). Pretreatment of RPTECs with insulin significantly increased the uptake of uric acid into these cells. The uric acid uptake was inhibited in a concentration-dependent manner by the URAT1 inhibitors benzbromarone and dotinurad. Therefore, effects of uricosuric agents can be evaluated by the novel method, which is closer to the physiological system compared with previous methods.

[1]  M. Yoshimura,et al.  URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice , 2021, Molecular metabolism.

[2]  Koji Matsumoto,et al.  Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity. , 2021, Bioorganic & medicinal chemistry letters.

[3]  I. Hisatome,et al.  Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia. , 2020, Circulation journal : official journal of the Japanese Circulation Society.

[4]  Koji Matsumoto,et al.  Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity. , 2020, ACS medicinal chemistry letters.

[5]  N. Osada,et al.  Dysfunctional missense variant of OAT10/SLC22A13 decreases gout risk and serum uric acid levels , 2019, Annals of the rheumatic diseases.

[6]  Koji Matsumoto,et al.  Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[7]  N. Xu,et al.  Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. , 2017, American journal of physiology. Renal physiology.

[8]  S. Zhuang,et al.  Recent advances on uric acid transporters , 2017, Oncotarget.

[9]  H. E. Meyer zu Schwabedissen,et al.  Regulation of PDZ domain-containing 1 (PDZK1) expression by hepatocyte nuclear factor-1α (HNF1α) in human kidney. , 2017, American journal of physiology. Renal physiology.

[10]  M. Hopps,et al.  Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[11]  A. Dominiczak,et al.  Allopurinol and Cardiovascular Outcomes in Adults With Hypertension , 2016, Hypertension.

[12]  K. Schenke-Layland,et al.  A human in vitro model that mimics the renal proximal tubule. , 2014, Tissue engineering. Part C, Methods.

[13]  O. Moe,et al.  Renal transport of uric acid: evolving concepts and uncertainties. , 2012, Advances in chronic kidney disease.

[14]  Ryo Matsushita,et al.  Enhanced renal clearance of vancomycin in rats with carcinogen-induced osteosarcoma. , 2012, Anticancer research.

[15]  Y. Shinohara,et al.  Decreased extra-renal urate excretion is a common cause of hyperuricemia , 2012, Nature Communications.

[16]  Hisashi Yamanaka,et al.  Japanese Guideline for the Management of Hyperuricemia and Gout: Second Edition , 2011, Nucleosides, nucleotides & nucleic acids.

[17]  B. Rovin,et al.  Uric acid and cardiovascular risk. , 2009, The New England journal of medicine.

[18]  Iain S Haslam,et al.  Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. , 2008, Toxicology and applied pharmacology.

[19]  F. Russel,et al.  The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.

[20]  T. Ogihara,et al.  Concentration-Dependent Mode of Interaction of Angiotensin II Receptor Blockers with Uric Acid Transporter , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  Yoshikatsu Kanai,et al.  The Multivalent PDZ Domain-containing Protein PDZK1 Regulates Transport Activity of Renal Urate-Anion Exchanger URAT1 via Its C Terminus* , 2004, Journal of Biological Chemistry.

[22]  V. Ganapathy,et al.  Expression of slc5a8 in Kidney and Its Role in Na+-coupled Transport of Lactate* , 2004, Journal of Biological Chemistry.

[23]  Hirotaka Matsuo,et al.  Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.

[24]  R. Bigazzi,et al.  Effect of insulin on renal sodium and uric acid handling in essential hypertension. , 1996, American journal of hypertension.

[25]  G. Reaven,et al.  Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. , 1991, JAMA.

[26]  R. N. Brogden,et al.  Benzbromarone: A Review of its Pharmacological Properties and Therapeutic Use in Gout and Hyperuricaemia , 1977, Drugs.

[27]  G. Poole,et al.  Hyperuricaemia Due to Pyrazinamide , 1960, British medical journal.

[28]  K. Tatsumi,et al.  A novel xanthine dehydrogenase inhibitor (BOF-4272). , 1991, Advances in experimental medicine and biology.

[29]  G. Boss,et al.  Hyperuricemia and gout. Classification, complications and management. , 1979, The New England journal of medicine.